Anti-Tick-Borne Encephalitis Virus Activity of Novel Uridine Glycoconjugates Containing Amide or/and 1,2,3-Triazole Moiety in the Linker Structure

Journal: Pharmaceuticals • • MDPI AG • ISSN: 1424-8247

Abstract

Tick-borne encephalitis virus (TBEV) transmitted by ticks is a pathogen of great medical importance. As still no effective antiviral treatment is available, in the present study, a series of uridine glycoconjugates containing amide or/and 1,2,3-triazole moiety in the linker structure was synthesized and evaluated for the antiviral activity against two strains of TBEV: a highly virulent Hypr strain and less virulent Neudoerfl strain, using standardized previously in vitro assays. Our data have shown that four compounds from the series (<b>18–21</b>) possess strong activity against both TBEV strains. The half maximal inhibitory concentration (IC<sub>50</sub>) values of compounds <b>18–21</b> were between 15.1 and 3.7 μM depending on the virus strain, which along with low cytotoxicity resulted in high values of the selectivity index (SI). The obtained results suggest that these compounds may be promising candidates for further development of new therapies against flaviviruses.

Subjects & Keywords

How to Cite this Article

Gabriela Brzuska, Gabriela Pastuch-Gawolek, Monika Krawczyk, et al. (2020). "Anti-Tick-Borne Encephalitis Virus Activity of Novel Uridine Glycoconjugates Containing Amide or/and 1,2,3-Triazole Moiety in the Linker Structure". Pharmaceuticals. https://doi.org/10.3390/ph13120460